immunotherapy

Young Kim, MD, PhD, left, Michael Korrer, PhD, and colleagues are studying a potential new cancer immunotherapy option.

Discovery points to new cancer immunotherapy option

An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.

GE Healthcare, Vanderbilt University Medical Center partner for safer, more precise immunotherapy cancer treatment

GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies.

Breast cancer-killing RIG

A compound that activates a virus-sensing receptor has potent therapeutic effects in a mouse model of breast cancer.

Immunotherapies linked to specific heart complications

In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.

Team’s findings show glutamine metabolism affects T cell signaling

The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered.

Mary Kay Foundation grant to bolster immunotherapy research

An immunotherapy research initiative at Vanderbilt University Medical Center is among those being supported by the Mary Kay Foundation, which has announced $1.2 million in funding that will be equally shared among 12 cancer research institutions.

1 2 3 4 5